StageZero Life Sciences Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SZLSF research report →
About the company
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada.
- CEO
- James R. Howard-Tripp
- IPO
- 2009
- Employees
- 40
- HQ
- Richmond Hill, ON, CA
Price Chart
- Market Cap
- $630.02K
- P/E
- -0.05
- P/S
- 0.17
- P/B
- -0.07
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
- Gross Margin
- -10.64%
- Op Margin
- -204.13%
- Net Margin
- -300.79%
- ROE
- 481.50%
- ROIC
- 151.84%
- Revenue
- $3.80M · -25.12%
- Net Income
- $-11,415,372 · -52.53%
- EPS
- $-0.11 · -10.00%
- Op Income
- $-7,746,761
- FCF YoY
- 61.24%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.00
- Beta
- 0.35
- Avg Volume
- 391.576
Get TickerSpark's AI analysis on SZLSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our SZLSF coverage
Recent articles, reports, and earnings notes.
No research on SZLSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SZLSF report →Similar companies
Peers in the same neighborhood.